Mark S Todtenkopf

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 6

Top Topics

Bipolar Disorder

Top Venues

Neuropsychiatric disease and treatment

Drug development research

The mental health clinician

This page only lists publications with an associated author ORCID identifier.

Publications

Mark S Todtenkopf, Christoph U Correll, Marni E Harris-White, Michael J Doane, David McDonnell
Comment on "Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review". The mental health clinician 13 (4) (2023)
Roger S McIntyre, Citrome Leslie, Hannah Cummings, Mark S Todtenkopf, Laura A Tan, Marni White, Sarah C Akerman
Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine. CNS spectrums (2022)
Citrome Leslie, Christine Graham, Adam Simmons, Ying Jiang, Mark S Todtenkopf, Bernard L Silverman, Lauren DiPetrillo, Hannah Cummings, Lei Sun, David McDonnell
An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder. Neuropsychiatric disease and treatment 17 (2021)
Citrome Leslie, Joseph P McEvoy, Mark S Todtenkopf, David McDonnell, Peter J Weiden
A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatric disease and treatment 15 (2019)
Mario P Sgro, Deah L Modlin, Daniel R Deaver, Mary J Kallman, Mark S Todtenkopf
Evaluation of samidorphan, a μ-opioid antagonist, in a drug discrimination assay in rats. Drug development research 79 (5) (2018)
Marta Peciña, Jordan F Karp, Sanjay Mathew, Mark S Todtenkopf, Elliot W Ehrich, Jon-Kar Zubieta
Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Molecular psychiatry 24 (4) (2018)